Repare Therapeutics has entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery ...

Repare Therapeutics Inc.’s RPTX share price has surged by 5.60%, which has investors questioning if this is right time to ...

CAMBRIDGE, Mass. & MONTREAL, May 01, 2025--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading clinical-stage precision oncology company ...

A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific ...

Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain ...